Ecstasy produces left ventricular dysfunction and oxidative stress in rats

Cardiovascular Research

Volumn 79, Issue 4, 2008, Pages 662-670

  Shenouda, Sylvia K ^a   Lord, Kevin C ^a,b   McIlwain, Elizabeth ^a,b   Lucchesi, Pamela A ^a   Varner, Kurt J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiac myocytes; Ecstasy; MDMA; Pressure volume loops; Proteomics; Tyrosine nitration

Indexed keywords

3 NITROTYROSINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA TROPOMYOSIN; MITOCHONDRIAL PROTEIN; MYOSIN LIGHT CHAIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONDUCTANCE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROSTIMULATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE RELAXATION; IN VIVO STUDY; MALE; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; RAT;

ANIMALS; CALCIUM SIGNALING; CELLS, CULTURED; DIASTOLE; DILATATION, PATHOLOGIC; ELECTRIC STIMULATION; HALLUCINOGENS; HEART VENTRICLES; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MUSCLE PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SYSTOLE; TYROSINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 52449125352     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn129     Document Type: Article

References (44)

1. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E et al. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 2002;76:581-588.
2. Colado MI, Green AR. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol 1995;280:343-346.
3. Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasheras B. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 1999;10:3675-3680.
4. Gudelsky GA. Effect of ascorbate and cysteine on the 3,4- methylenedioxymethamphetamine-induced depletion of brain serotonin. J Neural Transm 1996;103:1397-1404.
5. Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E et al. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 1995;21:169-176.
6. Montiel-Duarte C, Ansorena E, Lopez-Zabalza MJ, Cenarruzabeitia E, Iraburu MJ. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine ('ecstasy') on hepatic stellate cells. Biochem Pharmacol 2004;67:1025-1033.
7. Ninkovic M, Malicevic Z, Selakovic V, Simic I, Vasiljevic I. N-methyl-3,4-methylenedioxyamphetamine-induced hepatotoxicity in rats: oxidative stress after acute and chronic administration. Vojnosanit Pregl 2004;61:125-131.
8. Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. BMJ 2003;326:80-81.
9. Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with 'ecstasy' and 'eve' misuse. J Clin Pathol 1996;49:149-153.
10. Duflou J, Mark A. Aortic dissection after ingestion of 'ecstasy' (MDMA). Am J Forensic Med Pathol 2000;21:261-263.
11. Lai TI, Hwang JJ, Fang CC, Chen WJ. Methylene 3, 4 dioxymethamphetamine- induced acute myocardial infarction. Ann Emerg Med 2003;42:759- 762.
12. Madhok A, Boxer R, Chowdhury D. Atrial fibrillation in an adolescent-the agony of ecstasy. Pediatr Emerg Care 2003;19:348-349.
13. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992;340:384-387.
14. Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart 2001;85:E10.
15. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J Pharmacol Exp Ther 2002;302:898-907.
16. Patel MM, Belson MG, Wright D, Lu H, Heninger M, Miller MA. Methylene-dioxymethamphetamine (ecstasy)-related myocardial hypertrophy: an autopsy study. Resuscitation 2005;66:197-202.
17. Nishida N, Ikeda N, Kudo K, Esaki R. Sudden unexpected death of a methamphetamine abuser with cardiopulmonary abnormalities: a case report. Med Sci Law 2003;43:267-271.
18. Varner KJ, Ogden BA, Delcarpio J, Meleg-Smith S. Cardiovascular responses elicited by the 'binge' administration of methamphetamine. J Pharmacol Exp Ther 2002;301:152-159.
19. Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal methamphetamine- associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol 2003;41:981-986.
20. McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'): a controlled study in humans. Neuropsychopharmacology 1994;10:129-138.
21. Tiangco DA, Lattanzio FA Jr, Osgood CJ, Beebe SJ, Kerry JA, Hargrave BY. 3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB, increases intracellular calcium, and modulates gene transcription in rat heart cells. Cardiovasc Toxicol 2005;5:301-310.
22. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000;13:135-160.
23. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988;149:159-163.
24. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-345.
25. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci 1992;648:371-382.
26. Dowling GP, McDonough ET 3rd, Bost RO. 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. Jama 1987;257:1615-1617.
27. Rothstein EC, Byron KL, Reed RE, Fliegel L, Lucchesi PA. H2O2-induced Ca overload in NRVM involves ERK1/2 MAP kinases: role for an NHE-1-dependent pathway. Am J Physiol Heart Circ Physiol 2002;283:H598-H605.
28. 2 in rat cardiac myocytes. Am J Physiol Cell Physiol 2001;281:C1542-C1550.
29. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 1993;18:195-199.
30. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ('ecstasy') after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000;23:396-404.
31. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999;290:136-145.
32. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998;19:241-251.
33. Mihm MJ, Yu F, Reiser PJ, Bauer JA. Effects of peroxynitrite on isolated cardiac trabeculae: selective impact on myofibrillar energetic controllers. Biochimie 2003;85:587-596.
34. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104:174-180.
35. 2+ transport. Circ Res 2003;93:487-490.
36. Lokuta AJ, Maertz NA, Meethal SV, Potter KT, Kamp TJ, Valdivia HH et al. Increased nitration of sarcoplasmic reticulum Ca-ATPase in human heart failure. Circulation 2005;111:988-995.
37. Viner RI, Ferrington DA, Williams TD, Bigelow DJ, Schoneich C. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca-ATPase in skeletal muscle. Biochem J 1999;340:657-669.
38. Pearce LL, Kanai AJ, Epperly MW, Peterson J. Nitrosative stress results in irreversible inhibition of purified mitochondrial complexes I and III without modification of cofactors. Nitric Oxide 2005;13:254-263.
39. Guidarelli A, Fiorani M, Cantoni O. Enhancing effects of intracellular ascorbic acid on peroxynitrite-induced U937 cell death are mediated by mitochondrial events resulting in enhanced sensitivity to peroxynitrite- dependent inhibition of complex III and formation of hydrogen peroxide. Biochem J 2004;378:959-966.
40. Cassina A, Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys 1996;328:309-316.
41. Radi R, Cassina A, Hodara R, Quijano C, Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002;33:1451- 1464.
42. Jiang JP, Downing SE. Catecholamine cardiomyopathy: review and analysis of pathogenetic mechanisms. Yale J Biol Med 1990;63:581-591.
43. Carvalho M, Remiao F, Milhazes N, Borges F, Fernandes E, Monteiro Mdo C et al. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem Res Toxicol 2004;17:623-632.
44. Carvalho M, Remiao F, Milhazes N, Borges F, Fernandes E, Carvalho F et al. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 2004;200:193-203.